Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 09:39pm CET

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

Stocks mentioned in the article : Merck KGaA, Bayer AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
01/19 SANOFI : Appoints Dominique Carouge Executive Vice President Head of Business Tr..
01/19 SANOFI : Researchers from Sanofi Pasteur Report Findings in Mycoplasma (Validati..
01/19 SANOFI : Researchers from Sanofi Pasteur Describe Findings in Rabies Virus (A no..
01/19 REGENERON PHARMACEUTICALS : and Sanofi To Accelerate and Expand Investment for C..
01/19 NEW DENGUE HEMORRHAGIC FEVER FINDING : Insights From Phase III...
01/18 SANOFI : EDITORIAL - Sober approach
01/18 SANOFI : NBI to submit initial result of probe on Dengvaxia mess
01/17 SANOFI : Palace welcomes P1.4-B refund for unused Dengvaxia
01/17 SANOFI : Duque insists on full refund of govt payment for Dengvaxia
01/17 SANOFI TAPS TRINETX TO UP EFFICIENCY : Were at a stage of true transformation
More news
News from SeekingAlpha
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
01/17 De-Risking Catalysts Aplenty - Cara Therapeutics
01/17 VERTEX PHARMACEUTICALS : Set To Wow In '18
01/16 WALL STREET BREAKFAST : More Records In Store For Equities
01/14 CDC : Worst flu season in years
Financials (€)
Sales 2017 35 761 M
EBIT 2017 9 145 M
Net income 2017 7 967 M
Debt 2017 5 749 M
Yield 2017 4,18%
P/E ratio 2017 11,45
P/E ratio 2018 15,93
EV / Sales 2017 2,72x
EV / Sales 2018 2,67x
Capitalization 91 413 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 29
Average target price 83,9 €
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI0.72%112 074
JOHNSON & JOHNSON5.20%394 704
NOVARTIS0.61%224 711
PFIZER2.65%220 487
ROCHE HOLDING LTD.-5.40%210 743
MERCK AND COMPANY10.24%166 723